The National Cooperative Dialysis Study (NCDS) showed that morbidity of patients on chronic hemodialysis depended on urea removal during the hemodialysis sessions (1) . Urea kinetic analysis as a means of assessing adequacy of hemodialysis was introduced by a post facto analysis of the NCDS data (2) . A retrospective analysis of a large data base from a registry showed convincingly that the delivered dose of hemodialysis, measured as Kt/V urea, is a strong predictor of survival (3) . The realization that large body size (large V) secondary to obesity is another strong predictor of survival in hemodialysis (4, 5) raised the question whether the formula used to estimate adequacy of hemodialysis should be the urea product (Kt) instead of Kt/V urea (6) . A second retrospective analysis of a large registry data base confirmed the independent beneficial effect of obesity on the survival of hemodialysis patients, but also demonstrated convincingly a strong association between Kt/V urea and survival of hemodialysis patients with similar degrees of obesity (7) . The main legacies from the hemodialysis literature are that Kt/V urea is an appropriate way to assess adequacy of the procedure and that survival of the patients is the primary outcome of adequacy studies.
A form of urea kinetic analysis was introduced as an indicator of adequacy of peritoneal dialysis (PD) by Teehan et al (8) . A few years later, Keshaviah et al introduced the concept of Kt/V urea in PD (9) . The early years of urea kinetic analysis in PD were characterized by the belief that renal and peritoneal urea clearance are equivalent and by the absence of studies with adequate numbers of subjects analyzing the relevance of Kt/V urea in PD.
The CANUSA study was the first prospective, longitudinal, multicenter analysis of small solute clearances, including Kt/V urea and creatinine clearance (CCr), as indices of adequacy of PD. This study found an association between either Kt/V urea or CCr and morbidity or mortality in PD patients (10) . However, a subsequent analysis of the data from the same study revealed that only residual renal function, and more specifically urine volume, was associated to the outcomes (11) . A retrospective analysis of a large PD data set confirmed both the association between residual renal function and outcomes of PD and the absence of an association between peritoneal small solute clearances and outcomes (12) . These studies (11, 12) raised doubts about the equivalence between the renal and peritoneal clearances of small solutes. The main problems of both studies was their observational nature and the narrow ranges of the observed peritoneal Kt/V urea and CCr values.
The critical question regarding the use of small solute clearances as criteria of PD adequacy is whether replacement of lost renal clearance by equivalent amounts of peritoneal clearance prevents adverse outcomes. Until recently, attempts to answer this question consisted of small retrospective studies, all of which found a beneficial effect on patient survival of replacement of lost renal clearance by peritoneal clearance (13) (14) (15) . There was a need for a prospective randomized study with adequate numbers of subjects. In this regard, the recently published ADEMEX study (16) filled a large void in the literature. A review of the main findings of this landmark study, which will influence PD practices, is a worthy exercise.
The main findings of the ADEMEX study
The ADEMEX study analyzed the clinical course of 965 Mexican patients on PD randomly assigned, on a 1:1 basis, to an intervention group, which received increases in the PD dose designed to maintain total CCr above 60 L/1.73 m 2 weekly as renal function deteriorated, and a control group, which received the same CAPD dose (4 daily exchanges with 2 L fill volume) throughout the study period, which lasted a minimum of 2 years. The two groups did not differ in baseline demographic, anthropometric and clinical characteristics, and maintained throughout the study period a significant difference in Kt/V urea and CCr, with the intervention group having adequate values by current guidelines.
The number of deaths during the study period (157 in the control group and 159 in the intervention group) was sufficient for the analysis of the primary end point, survival. The main finding of the study was the absence of an effect of the dose on PD on patient survival. By multivariate Cox regression analysis, the predictors of survival in the ADEMEX study were age, diabetes mellitus, serum albumin as a time-dependent factor, and renal Kt/V urea or CCr, while peritoneal Kt/V urea or CCr had no predictive value and normalized protein nitrogen appearance (nPNA) had a marginal predictive value.
The ADEMEX study had also some secondary outcomes, which are relevant to the use of small solute clearances as indices of PD adequacy. We will use these outcomes and findings from early studies on hemodialysis adequacy to construct a list of the criteria of PD adequacy. We will start with a discussion of mortality as a criterion of dialysis adequacy.
Mortality as a criterion of dialysis adequacy
Mortality is an obligatory criterion for assessing adequacy of any life-sustaining procedure. The association between Kt/V urea delivered by hemodialysis and mortality was discussed earlier. An argument for considering mortality as a primary outcome of PD has been presented (17) . The use of mortality as the sole, or major, criterion for assessing adequacy of PD depends on whether the major influence on patient survival, within the range of the delivered PD doses, is the dose of PD. If not, other influences have a greater effect on mortality, which then becomes an insensitive index of adequacy.
A prospective analysis of Dutch patients starting PD revealed that mortality was primarily related to comorbidity, while the rate of small solute removal had a smaller, but statistically significant effect (18, 19) . Given the major effect of comorbidity on the survival of PD patients, it is possible that subtle, unaccounted for, differences in comorbidity obscured real effects of the dose of PD on mortality in the ADEMEX study.
Future analyses of adequacy of PD will need to take into detailed account the presence and severity of comorbid conditions. A proper way would be to stratify the patients according to comorbidity and analyze the effect of the PD dose on mortality in each stratified segment of the PD population. It is of interest that application of this approach to the issue of obesity in hemodialysis produced stronger associations between Kt/V urea and mortality within each stratified by obesity population segment than in the total population studied (7) .
The outcome of the preceding discussion is that mortality, although indispensable as a measure of PD adequacy, is relatively insensitive and non-specific, and must be complemented by other, more sensitive criteria. It is our contention that criteria derived from replacement of specific renal functions are the most sensitive indices of adequacy of renal replacement therapies. The original report of the use of hemodialysis to treat chronic renal failure (20) provides illuminating insights into these specific criteria. This report focused on the treatment of uremia, particularly its neurologic manifestations, and on nutrition, hypertension and abnormal responses to metabolic stimuli or drugs in dialysis patients. We will discuss below the relevance of these factors to the adequacy of PD.
Prevention of uremia and malnutrition as criteria of PD adequacy
The major concern of the initial application of hemodialysis in the treatment of chronic renal failure was reversal of the neurologic manifestations of uremia (20) . In the early stages of chronic hemodialysis, the clinical follow-up of patients emphasized the timely recognition of uremic manifestations. The appearance of a uremic manifestation resulted in increases in the dose of dialysis. The NCDS, which provided evidence linking the rate of removal of urea by hemodialysis with the appearance of uremic manifestations, and a change in the philosophy of dialysis practitioners, who came to realize that the aim of dialysis is not to treat, but to prevent uremia, were the reasons for using the rate of urea removal as the main index of adequacy of chronic hemodialysis. An interesting aside is that the use of urea kinetics to define adequacy of chronic dialysis has increased both the responsibility of the clinicians, because the appearance of uremic manifestations signifies failure of the delivered dialysis dose, and the diagnostic difficulties, because of the need of early detection of uremic manifestations which therefore are subtle. In any event, a dose of dialysis allowing the appearance of uremic manifestations even in a small fraction of a dialysis population must be considered as inadequate by today's thinking.
The ADEMEX study provided some information about inadequate levels of small solute clearances in PD. In this study, the intervention group received a total weekly Kt/V urea of 2.27±0.02 (peritoneal Kt/V urea 2.13±0.01) and a total weekly CCr of 62.9±0.7 L/1.73 m 2 (peritoneal CCr 56.9±0.48 L/1.73 m 2 ). The control group received a total weekly Kt/V urea of 1.80±0.02 (peritoneal Kt/V urea1.62±0.01) and a total weekly CCr of 54.1±1.0 L/1.73 m 2 (peritoneal CCr 46.1(0.45 L/1,73 m 2 ). As noted, mortality did not differ between the two groups. However, the appearance of uremic manifestations during the study period did differ. In the control group, 8.9% of the patients developed uremic manifestations leading to either withdrawal from the study or death compared to 1.7% in the intervention group. The differences between the two groups in both withdrawal from the study and death from uremic manifestations were significant. Hopefully a detailed report regarding the nature of the uremic manifestations leading to withdrawal from the study or death will be given. Nevertheless, based on the information provided a total weekly Kt/V urea of 1.8 and CCr of 54 L/1.73 m 2 appear to be inadequate in preventing the development of uremia in about 10% of the PD patients.
Malnutrition is common in patients on chronic dialysis and has multiple etiologies, including uremic anorexia and metabolic acidosis. An adequate dose of PD should reverse/prevent uremic malnutrition. It is also probable that the dose of PD has indirect effects on malnutrition secondary to other causes, for example malnutrition in patients with the chronic inflammatory syndrome. Further studies are needed in this important area. One specific questions that will need to be addressed is whether prevention of malnutrition requires higher doses of PD in certain subsets of PD populations.
Regulation of the extracellular volume as a criterion of PD adequacy
Despite its great impact on the survival of patients on chronic dialysis, prevention of chronic extracellular volume expansion has not received appropriate attention as a criterion of PD adequacy. There is a well known association between extracellular volume expansion, hypertension, left ventricular hypertrophy and dilatation, and mortality in patients on chronic dialysis. Approximately 25% of PD patients develop at least one episode of symptomatic extracellular volume expansion (21) . Although this acute symptomatic fluid retention may cause life-threatening manifestations, chronic volume expansion, which has subtler clinical manifestations, may have a more pronounced effect on the survival of PD patients. Hypertension is frequent in PD populations (22) and is a predictor of mortality (19) . In one study, 38% of the PD patients had hypertension because of volume expansion (23) . In another study, left ventricular failure was found more frequently in long-term CAPD patients than in longterm hemodialysis patients and was associated with poor control of blood pressure, despite the more frequent use of antihypertensive medications in the CAPD group (24) .
Daily hemodialysis, which provides better control of extracellular volume than any other dialytic modality, leads to reductions in left ventricular hypertrophy (25) . There are strong indications that prevention of extracellular volume expansion will have major beneficial effects on the morbidity and mortality of PD patients. Although these effects of volume control will need to be proven by appropriate studies, we suggest that control of extracellular volume is a major criterion of PD adequacy. Control of extracellular volume can be obtained by appropriate prescription of the PD schedule and the tonicity of PD solutions based on formal testing of peritoneal transport, and by dietary prescription. Limitation of salt intake is critical in the prevention of extracellular expansion (21) .
Management of anemia as a criterion of PD adequacy
The introduction of erythropoietin has revolutionized the management of anemia in patients on chronic dialysis. There is mounting evidence that timely and adequate treatment of anemia has beneficial effects on left ventricular hypertrophy and dilatation in patients on chronic dialysis. Registry reports have documented progressive increases in the mean blood hemoglobin concentration of patients on chronic dialysis in recent years. In the period October 2000 to March 2001, median blood hemoglobin concentration in American PD patients was 11.7 gm/dl, with 74% of the patients having blood hemoglobin ≥ 11 gm/dl (26). Thus, even though the management of anemia in PD patients is improving, onefourth of the PD patients in the USA still have suboptimal blood hemoglobin levels. Management of anemia should be considered a major criterion of adequacy of any renal replacement therapy because of its clinical importance.
Management of metabolic abnormalities as a criterion of PD adequacy
The statement in Scribner's original report (20) that chronic dialysis patients are ideal subjects to study non-renal actions of drugs and hormones was prophetic. Forty-two years later, the abnormalities in the extrarenal metabolism of calcium and phosphorus in chronic renal failure, which cause multiple bone diseases and extraosseous calcifications, remain an unsolved and evolving problem. Recently, emphasis has been placed on vascular calcifications. Control of enteric absorption of phosphorus based on intake of calcium salts was shown to be associated with coronary artery calcifications and coronary events (27) . Use of a phosphate-binding agent not based on calcium slows the progression of aortic and coronary calcifications (28) . If these findings are shown to translate into a reduction in vascular morbidity and mortality, control of calcium-phosphorus metabolism for the prevention of uremic vascular calcifications will be established as a major criterion of dialysis adequacy.
CONCLUSIONS
The kidneys perform multiple vital functions. Consequently, the notion of adequacy of renal replacement methods should also have multiple dimensions, as originally suggested by Scribner (20) . The list of criteria of adequacy of renal replacement methods should contain some criteria based on these specific vital renal functions. In addition, there should be general criteria of adequacy, more or less, applicable, to all life-sustaining therapies. Table I shows the proposed criteria of PD adequacy. Prevention of uremia remains a powerful, and probably along with control of the extracellular volume, the most sensitive criterion of PD adequacy. The ADEMEX study provided some evidence that a delivered total Kt/V urea of 1.8 weekly is not adequate in preventing uremia. It is prudent to aim at a higher level of Kt/V urea, probably 2.0 weekly or higher. High levels of Kt/V urea (and adequate ultrafiltration levels) are obtained in patients losing residual renal function by progressive increases in the volume and, when appropriate, the tonicity of the prescribed dialysate load. Shortening of the dwell time is often necessary. These maneuvers increase both the intraabdominal volume and the exposure of the peritoneum to high concentrations of glucose, with resulting symptoms from increased intraperitoneal pressure (16) , peritoneal membrane deterioration (29) , and metabolic abnormalities secondary to the absorption of large amounts of glucose into the circulation (30) . Thus the efforts to prevent uremia have important adverse effects, which in some instances could counterbalance their benefits. Success of the efforts to develop more biocompatible dialysates could lead to improvement of several of the indices of adequacy shown in Table I 
